.png){kind=icon}
.png){kind=icon}
Return
Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases
.png){kind=icon}
OA
AI
A
E
E
I
F
DOI：10.1007/s11912-026-01806-2.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Sacizuzumab Tirumotecan is a novel antibody-drug conjugate targeting TROP2 glycoprotein, which is highly expressed across malignant cells. Sacizuzumab Tirumotecan has already demonstrated promising clinical activity in combating breast and lung cancer, and it is currently under evaluation for use against gynecologic malignancies. This review aims to highlight the therapeutic potential of Sacituzumab Govitecan in gynecologic malignancies and to summarize the most recent evidence supporting its clinical application. Ongoing phase III trials of Sacituzumab Tirumotecan include cervical, ovarian, and endometrial cancers. Preliminary safety data of Sacituzumab Tirumotecan indicates a manageable toxicity profile, with the most commonly reported adverse events including hematologic toxicity, oral mucositis, and alopecia. Mature data from Phase III trials are anticipated to clarify the impact of Sacituzumab Tirumotecan on overall survival, progression-free survival, and objective response rates. Additionally, biomarker analyses may enhance patient selection strategies and refine prognostic assessment in gynecologic oncology. Antibody-drug conjugates (ADCs) are an advent in the management of oncology patients. Sacituzumab Tirumotecan (sac-TMT/MK-2870/SKB264) is a promising new ADC undergoing clinical trials in solid tumors. Promising results have been published with the use of Sacituzumab Tirumotecan in gynecologic malignancies, mainly cervical, ovarian and endometrial cancers. More mature data from phase III trials are expected soon.
Keywords:
Sacituzumab tirumotecan
Sac-TMT
MK-2870
Cervical
Ovarian
Endometrial
Antibody drug conjugates
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5
Papers:
694
Citations:
5.5K
Organization
Cited Papers